NCT06932562: An ongoing trial by European Myeloma Network B.V.
This trial is ongoing. It must report results 12 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06932562 |
|---|---|
| Title | A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2025 |
| Completion date | Dec. 31, 2036 |
| Required reporting date | Dec. 31, 2037, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |